**Zeitschrift:** Acta Tropica

**Herausgeber:** Schweizerisches Tropeninstitut (Basel)

**Band:** 44 (1987)

**Heft:** (12): Prospects for immunological intervention in human

schistosomiasis

**Vorwort:** Introduction

**Autor:** Bergquist, N.R.

## Nutzungsbedingungen

Die ETH-Bibliothek ist die Anbieterin der digitalisierten Zeitschriften auf E-Periodica. Sie besitzt keine Urheberrechte an den Zeitschriften und ist nicht verantwortlich für deren Inhalte. Die Rechte liegen in der Regel bei den Herausgebern beziehungsweise den externen Rechteinhabern. Das Veröffentlichen von Bildern in Print- und Online-Publikationen sowie auf Social Media-Kanälen oder Webseiten ist nur mit vorheriger Genehmigung der Rechteinhaber erlaubt. Mehr erfahren

### **Conditions d'utilisation**

L'ETH Library est le fournisseur des revues numérisées. Elle ne détient aucun droit d'auteur sur les revues et n'est pas responsable de leur contenu. En règle générale, les droits sont détenus par les éditeurs ou les détenteurs de droits externes. La reproduction d'images dans des publications imprimées ou en ligne ainsi que sur des canaux de médias sociaux ou des sites web n'est autorisée qu'avec l'accord préalable des détenteurs des droits. En savoir plus

#### Terms of use

The ETH Library is the provider of the digitised journals. It does not own any copyrights to the journals and is not responsible for their content. The rights usually lie with the publishers or the external rights holders. Publishing images in print and online publications, as well as on social media channels or websites, is only permitted with the prior consent of the rights holders. Find out more

**Download PDF: 21.11.2025** 

ETH-Bibliothek Zürich, E-Periodica, https://www.e-periodica.ch

## WHO Secretariat

BERGQUIST, Dr N. R., Secretary of the Steering Committee of the Scientific Working Group on Schistosomiasis, TDR, WHO/HQ

CHEN, Dr Ming Gang, Medical Officer, Schistosomiasis and Other Trematode Infections, WHO/HQ

Davis, Dr A., Director, Parasitic Diseases Programme, WHO/HQ

DEVLIN, Mr D., Office of the Legal Council, WHO/HQ

DIXON, Mr H., Division of Epidemiological Surveillance and Health Situation and Trend Assessment, WHO/HQ

DUNNE, Dr J., Secretariat Committee on Research Involving Human Subjects, WHO/HQ

Gratchev, Dr V., Biologicals, Division of Diagnostic, Therapeutic and Rehabilitative Technology, WHO/HQ

HOUBA, Dr V., Immunology, Division of Communicable Diseases, WHO/HQ

LAFORCE, Dr M., Consultant, Expanded Programme on Immunization, WHO/HQ

MOTT, Dr K. E., Chief, Schistosomiasis and Other Trematode Infections, WHO/HQ (Secretary of the Scientific Working Group on Schistosomiasis)

# Introduction

Observations of the ingenious mechanisms by which adult schistosomes evade the immunological defence of the host began intensively about 20 years ago. Sophisticated approaches, such as those based on monoclonal antibodies and recombinant DNA techniques, have allowed researchers to begin unravelling the complex nature of immunity against different stages of this trematode. Several effector mechanisms, involving an array of effector cells, have been identified. In addition, the presence of blocking antibodies in the early phase of infection seems to upset the mechanisms that might otherwise be expected to lead to naturally acquired immunity. Research using animal models, such as the mouse and rat, has increased knowledge considerably but investigation of the immunology of primate schistosomiasis will have to be substantially expanded. Although the present proceedings provide ample evidence that an impressive body of information has been gathered, the goal has yet to be achieved. The fortuitous fact that schistosomes do not multiply in the host means that mor-

bidity is governed by the number of penetrating cercariae that survive and reach the egg-laying stage. This advantageous situation offers a unique possibility in that even a partially effective vaccine would be useful. Thus the quest for a vaccine against schistosomiasis is a realistic long-term approach for future control efforts.

Although more than 600 million people throughout the tropics are at risk of schistosome infection and of these about one third are actually infected, the disease is not a research priority in either developing or developed countries. Nevertheless, international donor agencies have spent close to US \$40 million on schistosomiasis research over the last 15 years. About 25% of this amount has been contributed by TDR, of which more than US \$4 million have been allocated to immunological research. National research councils and bilateral donor agencies are also providing research support, but the general trend at present is one of declining financial support. However, the success achieved towards a schistosomiasis vaccine is paralleled, in research on parasitic diseases, only in the field of malaria vaccine research. At the present rate of progress, it is conceivable that human vaccine trials could start in the early part of the next decade, but substantial funding will be required to comply with this time-frame. In addition, international coordination will be essential in order to avoid unnecessary duplication of effort and to ensure adequate evaluation of vaccine efficacy.

The sixteen lectures presented here were delivered upon invitation. In the interest of rapid communication, these papers have been submitted to only minimal editorial revision and this volume may therefore contain inconsistencies in style. The discussions following each presentation constituted an important part of the meeting but rather than presenting them in extenso, they have been integrated into an overview (p. 108–117), which summarizes the discussions and conclusions of the meeting.

N. R. Bergquist, Secretary of the Steering Committee of the Scientific Working Group on Schistosomiasis